Gene test may personalize breast cancer treatment before surgery
NCT ID NCT03749421
First seen Feb 06, 2026 · Last updated Apr 28, 2026 · Updated 11 times
Summary
This study looks at whether a genomic test called Prosigna can help doctors and patients choose the best treatment before breast cancer surgery. It involves 60 women with a specific type of breast cancer (HR+/Her2-). The main goal is to see if the test results change the treatment plan, aiming for more personalized care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.